Thermo Fisher Scientific beta Amyloid (1-20) Monoclonal Antibody (7N22)

Applications

Western Blot (WB)

• Tested Dilution: 1–3 µg/mL
• View 1 publication

ELISA

• Tested Dilution: Assay-dependent

Product Specifications

Target Information

Amyloid beta peptide (Abeta/Beta-amyloid) is the major constituent of amyloid plaques in the brains of individuals afflicted with Alzheimer’s disease. Abeta peptide is 40–43 amino acids long and generated from the beta-amyloid precursor protein (beta APP) in a two-step process.

The first step involves cleavage of the extracellular, amino-terminal domain of beta APP by beta-secretase (BACE), which must be modified to its mature and active form by the prohormone convertase, furin. Beta APP cleavage by mature BACE results in secretion of a beta APP segment and a membrane-bound remnant, which is further processed by gamma-secretase.

Gamma-secretase, a multi-subunit complex containing presenilin-1 and -2, cleaves an intra-membrane site in the carboxyl-terminal domain of beta APP, generating the amyloid beta peptide. Nicastrin, a transmembrane glycoprotein associated with presenilins, binds to the carboxyl-terminus of beta APP and modulates amyloid beta peptide production.

Abeta is an extracellular filamentous protein found in amyloid cores, neuritic plaques, and neurofibrillary tangles. Alzheimer’s disease, characterized by abnormal filamentous protein deposits in the brain, also shows beta amyloid deposits in Lewy body dementia, Down’s syndrome, Dutch-type amyloidosis, cerebroarterial amyloidosis (cerebral amyloid angiopathy), and the Guam Parkinson-Dementia complex.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.